此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

针对阈下抑郁老年人的虚拟现实园艺种植计划

2026年8月25日 更新者:Zhu Ziping、Fujian Medical University

一项基于虚拟现实的园艺种植计划对亚临床抑郁老年人的干预效果:一项随机对照预试验研究

阈下抑郁代表一种介于正常个体与临床抑郁症之间的心理亚健康状态。 它是发展为临床抑郁症的高风险阶段,也是缓解抑郁症状的关键时期。 然而,当前研究主要聚焦于治疗老年人的抑郁症,对高危人群干预的关注不足,或仅限于阈下抑郁危险因素的横断面调查。 因此,优先关注老年人的阈下抑郁并实施早期干预至关重要。 《柳叶刀》2024年的一篇文章指出,阈下抑郁的治疗应优先考虑心理治疗和生活方式调整,而非药物治疗。 园艺疗法是一种融合园艺学、医学和心理学的跨学科方法,相比传统医疗手段展现出独特优势。 但在实际应用中,资源有限可能阻碍对园艺活动的充分支持,影响活动质量,降低治疗效果,并限制园艺疗法的广泛推广。 将VR技术与园艺疗法相结合,可为患者提供更全面、个性化和有效的心理健康治疗方案,助力他们迈向更健康、更积极的生活。 因此,研究团队基于社会参与能力框架,为患有阈下抑郁的老年人设计了一套VR园艺干预系统。

研究概览

详细说明

阈下抑郁(SD)是介于正常个体和临床抑郁症之间的一种心理亚健康状态。它是发展为重度抑郁障碍的高风险阶段,也是缓解抑郁症状的关键窗口期。《美国医学会杂志》发表的一篇社论强调,阈下抑郁研究对于探索抑郁症的预防和治疗具有重要意义。因此,优先关注老年人的阈下抑郁并实施早期干预至关重要。多项研究表明,社会参与作为老年人抑郁的可改变因素之一,能够积极延缓老年抑郁的发生和进展。社会参与涵盖多维度的活动,老年人通过这些活动交换物质和情感资源,并获得社会认可。这些活动包括参与活动、履行社会角色、人际互动、利用社会资源以及恢复个人价值。退休、疾病或身体衰退等因素往往导致老年人现有社交网络变窄、社会联系减弱。这导致社会参与的范围和频率减少,可能引发或加剧抑郁障碍。相反,抑郁障碍本身通过情绪低落和兴趣减退等核心症状,进一步削弱老年人维持关系和积极参与活动的意愿和能力,形成恶性循环。2024年发表在《柳叶刀》上的一项研究表明,社会参与水平高的老年人抑郁风险显著低于参与水平低的老年人。同样,2023年《自然·老龄化》的一项研究指出,社会参与可能通过缓解压力、炎症和脑血管损伤来减少抑郁,从而维护大脑健康、构建认知储备并减轻抑郁障碍。

虚拟现实(VR)技术作为一种新型干预方法,具有沉浸性、交互性和模拟性三大特点。通过复制家庭和社区环境等真实世界场景,它丰富了老年抑郁患者的训练体验,帮助他们适应多样化的社会情境,并提升干预效果。园艺疗法是一种融合园艺学、医学和心理学的跨学科方法,治疗成本相对较低,副作用极小。它在促进身体康复、改善情绪健康和增强社交技能方面发挥着积极作用。越来越多的研究团队正在探索VR生成的虚拟园艺环境和园艺活动干预。VR技术解决了传统园艺疗法的多个局限。基于VR的园艺活动克服了时间和空间的限制,减少了实体园艺相关的成本和风险,并提供更丰富、更个性化的社交化园艺场景和活动,以满足不同患者的需求。因此,将VR技术与园艺疗法相结合,为患者提供了更全面、个性化和有效的心理健康治疗方案,帮助他们过上更健康、更积极的生活。

研究类型

介入性

注册 (实际的)

62

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Fuzhou
      • Fujian、Fuzhou、中国、350001
        • Nursing school of Fujian Medical university

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

描述

纳入标准:

  • 年龄 ≥ 60岁
  • 符合亚阈值抑郁诊断标准:在流行病学调查中使用的流行病学调查抑郁量表(CES-D)得分 ≥ 16分(此标准在同类研究中被广泛采用)
  • 视觉、听觉或言语无障碍
  • 知情同意

排除标准:

  • 胰岛素依赖型糖尿病
  • 甲状腺疾病
  • 近期经历重大创伤应激事件,无自杀风险
  • 当前正在参与其他类似研究
  • 临床诊断为抑郁症或精神分裂症等精神障碍
  • 当前正在服用抗抑郁药物
  • 严重认知障碍
  • 严重躯体疾病或器官性疾病,且自理能力受损

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:虚拟现实干预
该小组采用了一个基于园艺种植的虚拟现实干预系统,由研究团队设计和开发。
The system comprised six progressive horticultural tasks, each associated with a distinct plant: (1) Tomato Planting, (2) Corn Cultivation, (3) Strawberry Care, (4) Eggplant Harvest, (5) Rose Growing, and (6) Sunflower Expansion. All tasks followed the same eight standardized steps-land preparation, seed sowing, seedling fertilization, initial watering, secondary fertilization, secondary watering, pest removal, and harvesting-but were arranged in a clear gradient of increasing difficulty. This progression was reflected in expanding planting scales, escalating task complexity, heightened cognitive load, more refined judgment requirements, and varying demands on operational precision. Each task was performed individually by the participant using the VR headset, without any multiplayer or collaborative components, as the system was designed for personalized, self-paced intervention.
This arm of seniors maintains their daily routines and participates regularly in the nursing home's daily activities.
实验性的:Routine Care
The control group received routine health management over the 6-week period, which encompassed assistance with daily living activities, basic medical care (including regular health check-ups and medication management), recreational activities, and environmental cleaning, with no additional structured intervention.
This arm of seniors maintains their daily routines and participates regularly in the nursing home's daily activities.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Subthreshold Depression
大体时间:The intervention was conducted in November 2025, and the evaluation time was 0,6 weeks .

The Center for Epidemiological Surveys Depression Scale (CES-D) was developed by Rirodiff at the National Institute of Mental Health in the United States. It is designed for screening depressive symptoms in older adults, comprising 20 items. Each question assesses one symptom, covering 20 distinct symptoms in total. The total score ranges from 0 to 60 points. A score ≤15 indicates no depressive symptoms, 16-19 suggests possible depressive symptoms, and ≥20 confirms depressive symptoms. The Cronbach's alpha coefficient for the Chinese population is 0.90. It is one of the most commonly used subthreshold depression epidemiological survey tools, with existing studies defining CES-D ≥16 as subthreshold depression.

Translated with DeepL.com (free version)

The intervention was conducted in November 2025, and the evaluation time was 0,6 weeks .

次要结果测量

结果测量
措施说明
大体时间
General cognitive function
大体时间:The intervention was conducted in November 2025, and the evaluation time was 0,6 weeks separately.
The Montreal Coanitive Asessment Scale,developed by Nasreddine in 2004 to assess participants'general cognitive function, covers eight areasof cognitive assessment, including visuospatial and executive function, naming, memory, attention, speech, abstraction, delayed recall, andorientation. The Changsha version of the Montreal Cognitive Assessment Scale was used in this study, and its Cronbach's a coeficient was 0.846,retest reliability was 0.974, and investigator reliability was 0.969. The score of the Montreal Cognitive Assessment Scale ranges from 0 to 30points. The higher the score,the better the cognitive function ofthe study subjects. The iliterate group s13, the primary school group s19 and thejunior high school and above group s24 can be judged as impaired cognitive function to correct the bias caused by education level.
The intervention was conducted in November 2025, and the evaluation time was 0,6 weeks separately.
Anxiety Condition
大体时间:The intervention was conducted in November 2025, and the evaluation time was 0,6 weeks separately
The self-rating anxiety scale (SAS) was designed and developed by Zung in the United States in 1971 to assess the severity of anxiety symptoms in individuals. It demonstrates good reliability and validity, with a split-half reliability coefficient of 0.696, test-retest reliability of 0.777, and internal consistency of 0.82. Additionally, it exhibits good construct validity . The scale comprises 20 items, with items 5, 9, 13, 17, and 19 scored in reverse. The scale employs a 1-4 rating scale (1 = never or rarely; 2 = a small portion of the time; 3 = a considerable portion of the time; 4 = most or all of the time). Individuals complete the scale based on their experiences during the past week. The total score is multiplied by 1.25, rounded to the nearest whole number to obtain a standardized score, which serves as the statistical indicator. A higher standardized score indicates more severe anxiety levels
The intervention was conducted in November 2025, and the evaluation time was 0,6 weeks separately
Self-Efficacy
大体时间:The intervention was conducted in November 2025, and the evaluation time was 0,6 weeks separately.
The General Self-Efficacy Scale (GSES), developed by Schwarzer et al , was used. It consists of 10 items rated on a 4-point Likert scale, ranging from 1 (strongly disagree) to 4 (strongly agree). Higher total scores indicate higher levels of self-efficacy. In this study, the Cronbach α coefficient was 0.81.
The intervention was conducted in November 2025, and the evaluation time was 0,6 weeks separately.
Sleep Quality
大体时间:The intervention was conducted in November 2025, and the evaluation time was 0,6 weeks separately.
This study employed the Pittsburgh Sleep Quality Index (PSQI) developed by Buysse et al. in 1989 to assess patients' sleep quality over the preceding month. The 19-item questionnaire comprises seven components: subjective sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disturbances, hypnotic medication use, and daytime functioning. The total score ranges from 0 to 21, with higher scores indicating poorer sleep quality. The Cronbach's alpha coefficient for this scale is 0.85.
The intervention was conducted in November 2025, and the evaluation time was 0,6 weeks separately.
System Usability
大体时间:The intervention will be implemented in November 2025, with the evaluation conducted after the 6-week intervention period concludes.
System Usability Scale (SUS) Developed by Brooke et al., the scale used in this study is the Chinese version of the System Usability Scale translated and revised by Chinese scholars including Li Yongfeng. This scale is unidimensional and consists of 10 items. It employs a 5-point Likert scale, with scores ranging from 1 ("Strongly Disagree") to 5 ("Strongly Agree"). Positive items (Items 1, 3, 5, 7, 9) are scored positively: Actual item score = Item rating - 1. Negative items (Items 2, 4, 6, 8, 10) are scored negatively: Actual item score = 5 - Item rating. If an item is left blank, it is assigned a score of 3. The total scale score = sum of all item scores × 2.5. The scale has a maximum score of 100 points, with scores >60 considered usable, 70 considered good, ≥80 considered excellent, and ≥90 considered outstanding. The Cronbach's alpha coefficient for this scale is 0.91.
The intervention will be implemented in November 2025, with the evaluation conducted after the 6-week intervention period concludes.
Simulator Sickness
大体时间:The intervention will be implemented in November 2025, with the evaluation conducted after the 6-week intervention period concludes.
The Simulator Sickness Questionnaire(SSQ) developed by Kennedy et al. in 1993, is a widely used tool for assessing the subjective severity of simulator sickness symptoms. The SSQ consists of pre- and post-experiment sections. The pre-experiment section employs the Pensacola Motion Sickness Questionnaire (MSQ) to gather information about participants' current physical condition and prior simulator experience. The post-experiment section measures symptom severity on a four-point scale (0-3) for each symptom. SSQ items can be grouped into three factors: nausea (e.g., sweating, difficulty concentrating, gastric awareness), eye movement disturbances (e.g., headache, eye fatigue, blurred vision), and disorientation (e.g., head fullness, dizziness with eyes open/closed, vertigo). The SSQ can be scored in two ways: (1) Calculate the score for each factor by summing the scores of all relevant items (each factor includes 7 items), with a score range of 0-179.5
The intervention will be implemented in November 2025, with the evaluation conducted after the 6-week intervention period concludes.
Immersion Presence
大体时间:The intervention will be implemented in November 2025, with the evaluation conducted after the 6-week intervention period concludes.

The Immersion Presence Questionnaire (IPQ) was employed to evaluate users' sense of immersion in the experience. Developed by Schubert et al., this questionnaire was subsequently translated into Chinese and validated for reliability and validity by Liang Jiahui et al. The results demonstrated its strong reliability and validity, with a Cronbach's α coefficient of 0.82. The Chinese version comprises 13 items organized into three dimensions: spatial presence (Items 2, 3, 9), involvement (Items 1, 6, 10), and realism (Items 4, 5, 8, 11, 12, 13). Item 7 reflects overall presence. Each item employs a 7-point Likert scale ranging from -3 to 3 points, with items 10 and 12 reverse-scored. The total score ranges from -39 to 39 points, where a higher score indicates a better sense of presence experience in the virtual reality environment.

Item 7 reflects overall presence. Each item uses a 7-point Likert scale ranging from -3 to 3 points, with items 10 and 12 reverse-scored. The total score rang

The intervention will be implemented in November 2025, with the evaluation conducted after the 6-week intervention period concludes.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年11月10日

初级完成 (实际的)

2026年1月16日

研究完成 (实际的)

2026年1月16日

研究注册日期

首次提交

2025年11月27日

首先提交符合 QC 标准的

2025年12月9日

首次发布 (实际的)

2025年12月10日

研究记录更新

最后更新发布 (实际的)

2026年8月27日

上次提交的符合 QC 标准的更新

2026年8月25日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • K2025-06-025

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 共享支持信息类型

  • 研究方案

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅